Reuters logo
BRIEF-Mylan says EpiPen sales suffer from increased competition
May 10, 2017 / 3:35 PM / 6 months ago

BRIEF-Mylan says EpiPen sales suffer from increased competition

May 10 (Reuters) - Mylan

* President says EpiPen will account for less than 5 percent of global revenue and less than 10 percent of north american sales

* President says EpiPen will account for less than 5 percent of global revenue and less than 10 percent of north american sales in 2017 (adds year)

* Says still expects profits from EpiPen to be down $400 million in 2017 from last year Further company coverage: (Reporting By Michael Erman)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below